Related Experiment Video

Updated: Jun 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic agents in the prevention of ischemic stroke

Marie-Germaine Bousser1

  • 1Hôpital Lariboisière, APHP, Neurology Department, Paris, France. mg.bousser@lrb.aphp.fr

Cerebrovascular Diseases (Basel, Switzerland)
|May 15, 2009
PubMed

Insights

Antiplatelet drugs reduce the risk of stroke and heart attack by 25% in patients with artery disease. Oral anticoagulants are more effective for preventing stroke in nonvalvular atrial fibrillation (NVAF) but carry higher bleeding risks.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antithrombotic drugs are crucial for preventing cerebrovascular events.
  • Established therapies include antiplatelet agents (aspirin, clopidogrel) and vitamin K antagonists for oral anticoagulation.

Purpose of the Study:

  • To review the efficacy and risks of current antithrombotic strategies for cerebral infarction prevention.
  • To highlight the need for research into novel agents and combination therapies.

Main Methods:

  • Systematic review of existing literature on antiplatelet drugs and oral anticoagulants.
  • Comparative analysis of risk reduction and adverse events (hemorrhage).

Main Results:

  • Antiplatelet drugs reduce the relative risk of ischemic events by 25% in large- or small-artery disease.
  • Aspirin shows a 19% stroke risk reduction in primary prevention for women, but not men.
  • Oral anticoagulants reduce ischemic stroke risk by 65-70% in nonvalvular atrial fibrillation (NVAF) compared to placebo, and 40% compared to aspirin, but with increased hemorrhage risk.

Conclusions:

  • Antiplatelet agents are effective for secondary prevention in arterial disease.
  • Oral anticoagulants offer superior stroke prevention in NVAF but require careful risk-benefit assessment due to bleeding.
  • Further research is needed on new agents and combined therapies, especially in elderly patients with comorbid conditions.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...